Runhui Wu, PhD, MD

Professor
Department of Hematology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, 100045, China
Beijing, Beijing, China (People's Republic)

Professor Runhui Wu is a clinical Paediatrician Haematologist and the director in the Haematology Department of Beijing Children’s Hospital (BCH), affiliated to Capital Medical University, National Centre for Children’s Health, China, she is the director of the children Haemophilia Comprehensive Care Centre of China, setteled in BCH.
She focusses on children’s bleeding disorders, especially in Pediatric hemophilia work in China. Since 2005, she and her team have been exploring the low-dose to individualized prophylaxis, low-dose Immune tolerance induction (ITI) strategies, aim to explore rational use of limited medical resources, optimize the cost-effectiveness of treatment in China.

Presentation(s):

• OC 05.1 - Machine learning models developed and internally validated for predicting chronicity in pediatric immune thrombocytopenia

  Saturday, June 22, 2024
  13:00 – 13:15 ICT

• OC 13.4 - Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China

  Sunday, June 23, 2024
  10:15 – 10:30 ICT

• PB0256 - A novel complex gene rearrangement between F8 and chr10 causes moderate hemophilia A with a family history of inhibitor development

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0265 - Reduced doses of emicizumab achieve good efficacy: results from a national-wide multicenter real-world study in China

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• OC 21.6 - Novel hemophilia treatments, pre-clinical

  Sunday, June 23, 2024
  14:45 – 16:00 ICT

• PB0721 - Case Report: Clinical manifestations and therapeutic options following rhTPO-induced neutralizing antibody production in a child with immune thrombocytopenia

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0506 - Influence of F8 gene mutation on outcome in immune tolerance induction of hemophilia A children with inhibitors

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0604 - Plasma concentration-adjusted dose of eltrombopag for the individualised treatment of immune thrombocytopenia in children：apilot study from Beijing Children’s Hospital

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0621 - Population pharmacokinetics model of BAY81-8973 in Chinese children with severe haemophilia A

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0613 - Real-World Use of Emicizumab in Chinese Children with Hemophilia A: Retrospective Data from a Comprehensive Care Center

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0542 - Recommendation model to automatically assign immunosuppressants to low-dose immune tolerance induction individually in severe hemophilia A patients with inhibitors via causal inference

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0665 - Th1 cells is the predictive factor of early response to rituximab in children with immune thrombocytopenia

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0546 - The lower double negative T cells proportion predicted the better high-titer inhibitors eradication outcomes of immune tolerance induction

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• OC 40.1 - A Novel Extended half-life factor VIII Fc fusion protein FRSW107 for severe hemophilia A: A multicentre, open-label, single-arm, phase 3 study and its open-label extension

  Monday, June 24, 2024
  14:45 – 15:00 ICT

• OC 41.2 - F8 mutations involving deletion of the F8B gene increase inhibitor risk for hemophilia A

  Monday, June 24, 2024
  15:00 – 15:15 ICT

• OC 41.3 - Single-cell sequencing of PBMCs from hemophilia A and hemophilia B patients with inhibitors reveals different immune responses to FVIII and FIX after replacement therapy

  Monday, June 24, 2024
  15:15 – 15:30 ICT

• PB1256 - Escalating low-dose individualized haemophilia prophylaxis: A focus in China at Dawn of a new era of cost effective Individualized prophylaxis

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• OC 61.3 - More cost-effective of intermediate-dose immune tolerance induction regimen for severe hemophilia A children with high-titer inhibitors: the interim report of a randomized multicenter clinical trial

  Tuesday, June 25, 2024
  15:15 – 15:30 ICT